Literature DB >> 10528237

MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.

T A Williams1, P Longati, L Pugliese, P Gual, A Bardelli, P Michieli.   

Abstract

Ron and Met are structurally related receptor tyrosine kinases that elicit a complex biological response leading to invasive growth. Naturally occurring point mutations activate the Met kinase in papillary renal carcinomas (MET(PRC) mutations). By site-directed mutagenesis, we generated homologous amino acid substitutions in the Ron kinase domain and analyzed the biochemical and biological properties of the mutant receptors. Among the mutations studied, D(1232)H and M(1254)T displayed transforming activity in NIH3T3 cells, inducing focus formation and anchorage-independent growth. The D(1232)H and M(1254)T substitutions resulted in increased Ron autophosphorylation both in vivo and in vitro and constitutive binding to intracellular signal transducers. Both mutations yielded a dramatic increase in catalytic efficiency, indicating a direct correlation between kinase activity and oncogenic potential. Molecular modeling of the Ron D(1232)H mutation suggests that this single amino acid substitution favors the transition of the kinase from the inactive to the active state. These data demonstrate that point mutations can confer transforming activity to the Ron receptor and show that RON is a potential oncogene. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528237     DOI: 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

2.  Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.

Authors:  A Danilkovitch-Miagkova; A Miagkov; A Skeel; N Nakaigawa; B Zbar; E J Leonard
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

3.  Activation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk.

Authors:  Shihan He; Shuang Ni; Shailaja Hegde; Xin Wang; Daniel R Sharda; Avery August; Robert F Paulson; Pamela A Hankey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

4.  Ex vivo and in vivo biological effects of a truncated form of the receptor tyrosine kinase stk when activated by interaction with the friend spleen focus-forming virus envelope glycoprotein or by point mutation.

Authors:  Karen Rulli; Takashi Yugawa; Charlotte Hanson; Delores Thompson; Sandra Ruscetti; Kazuo Nishigaki
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 5.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 6.  Ron-receptor tyrosine kinase in tumorigenesis and metastasis.

Authors:  Mike A Leonis; Megan N Thobe; Susan E Waltz
Journal:  Future Oncol       Date:  2007-08       Impact factor: 3.404

7.  Transformation and scattering activities of the receptor tyrosine kinase RON/Stk in rodent fibroblasts and lack of regulation by the jaagsiekte sheep retrovirus receptor, Hyal2.

Authors:  A Dusty Miller; Neal S Van Hoeven; Shan-Lu Liu
Journal:  BMC Cancer       Date:  2004-09-13       Impact factor: 4.430

Review 8.  Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction.

Authors:  Ming-Hai Wang; Ruiwen Zhang; Yong-Qing Zhou; Hang-Ping Yao
Journal:  J Biomed Res       Date:  2013-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.